Merlin Biomed

Founded 1998
Founders Stuart T. Weisbrod

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 18
Average round size
info
The average size of a deal this fund participated in
$30M
Portfolio companies 10
Rounds per year 0.43
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 7
Stages of investment
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
Summary

Merlin Biomed appeared to be the Corporate Investor, which was created in 1998. The fund was located in North America if to be more exact in United States. The main office of represented Corporate Investor is situated in the New York.

Among the most popular fund investment industries, there are Health Care, Biopharma. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight ARIAD Pharmaceuticals, FibroGen, Calypso Medical. The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.

The average startup value when the investment from Merlin Biomed is 10-50 millions dollars. Opposing the other organizations, this Merlin Biomed works on 36 percentage points more the average amount of lead investments. The increased amount of exits for fund were in 2014. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2003. The fund is constantly included in less than 2 deals per year.

The fund was created by Stuart T. Weisbrod.

The usual cause for the fund is to invest in rounds with 8-9 partakers. Despite the Merlin Biomed, startups are often financed by Bay City Capital, Versant Ventures, Venrock. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, VantagePoint Capital Partners, OrbiMed. In the next rounds fund is usually obtained by OrbiMed, MPM Capital, Sanderling Ventures.

Read more

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Late Stage Venture
8M05 Nov 2009

Gemin X Pharmaceuticals

Biotechnology
Pharmaceutical
Therapeutics
Late Stage Venture
38M03 Jul 2008 Canada, Montreal

Late Stage Venture
32M19 Apr 2007

Calypso Medical

Health Care
Medical
Medical Device
Late Stage Venture
42M08 Jan 2007 United States, Seattle

EUSA Pharma

Biotechnology
Health Care
Medical
Pharmaceutical
Venture - Series Unknown
18M07 Nov 2006 United Kingdom, " United Kingdom"}

Biotechnology
Health Care
Medical
Venture - Series Unknown
40M07 Sep 2006 United States, " United States"}

Genelabs Technologies

Biopharma
Biotechnology
Health Care
Therapeutics
8M27 Jun 2006 United States, Redwood City

Affymax

Biopharma
Biotechnology
Health Care
Late Stage Venture
60M18 Jul 2005 United States, Cupertino

FibroGen

Biopharma
Biotechnology
Therapeutics
Venture - Series Unknown
100M17 Feb 2005 United States, San Francisco

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Merlin Biomed?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: